Long Term Follow up in Sickle Cell Patients Treated by Hydroxyurea.Observational Retrospective Study.
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- Sickle Cell Anemia
- Sponsor
- HaEmek Medical Center, Israel
- Enrollment
- 20
- Locations
- 1
- Status
- Completed
- Last Updated
- 16 years ago
Overview
Brief Summary
Hydroxyurea was found to be a good treatment in adult patients with sickle cell anemia with significant decrease in the frequency of vaso-occlusive crises and other crises related to SCA. Several studies were published with relative short term follow up in pediatric and young adult age. The purpose of this study is to assess the long term follow up in a group of patients that initiated Hydroxyurea treatment in childhood.
Detailed Description
Hydroxyurea was found to be a good treatment in adult patients with sickle cell anemia with significant decrease in the frequency of vaso-occlusive crises and other crises related to SCA. Several studies were published with relative short term follow up in pediatric and young adult age. The purpose of this study is to assess the long term follow up in a group of patients that initiated Hydroxyurea treatment in childhood. A long term follow up will be recorded in a cohort of twenty SCA patients treated by Hydroxyurea for a period between 5 to 12 years. The frequency of vaso-occlusive crises, acute chest syndrome, blood transfusions, and hospitalization will be recorded retrospectively. Also the mean hgb level and hgb F percentage will be summarized.
Investigators
Eligibility Criteria
Inclusion Criteria
- •All patients treated by Hydroxyurea in the Pediatric Hematology Unit.
Exclusion Criteria
- Not provided
Outcomes
Primary Outcomes
Not specified